TB-500 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-17. Anything still debated is marked as such rather than presented as settled.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
== Description == Sophora flavescens can grow to a height of 2 m (6.6 ft). Its stem is marked with stripes and covered in soft hairs when young. The leaves are usually 20–25 cm (8–10 in) long, with lanceolate stipules and 13–25 elliptic, ovate, or lanceolate leaflets. The plant produces terminal racemes measuring 15–25 cm (6–10 in), with numerous flowers spaced widely apart. The flowers have slender pedicels and linear bracts with white, pale yellow, purple-red, or red spoon-shaped petals. It blooms from June to August and fruits from July to October.
codon A series of three consecutive nucleotides in a coding region of a nucleic acid sequence. Each of these triplets codes for a particular amino acid or stop signal during protein synthesis. DNA and RNA molecules are each written in a language using four "letters" (four different nucleobases), but the language used to construct proteins includes 20 "letters" (20 different amino acids). Codons provide the key that allows these two languages to be translated into each other. In general, each codon corresponds to a single amino acid (or stop signal). The full set of codons is called the genetic code.
Mutagenesis experiment: The direct method to investigate the DFE is to induce mutations and then measure the mutational fitness effects, which has already been done in viruses, bacteria, yeast, and Drosophila. For example, most studies of the DFE in viruses used site-directed mutagenesis to create point mutations and measure relative fitness of each mutant. In Escherichia coli, one study used transposon mutagenesis to directly measure the fitness of a random insertion of a derivative of Tn10. In yeast, a combined mutagenesis and deep sequencing approach has been developed to generate high-quality systematic mutant libraries and measure fitness in high throughput. However, given that many mutations have effects too small to be detected and that mutagenesis experiments can detect only mutations of moderately large effect; DNA sequence analysis can provide valuable information about these mutations.
Metrohm was founded in 1943 in Herisau by Bertold Suhner and Willi Studer. At the outset, the company produced measuring instruments for high-frequency technology and telecommunications. High-precision measuring instruments as well as radio receivers were added to its product range later on. After World War II, the company struggled as the demand for their products decreased, since it was cheaper to buy imported radios from the US. Thus, Suhner decided to venture into analytical chemistry and developed a first pH meter in 1947, followed by a titrator in 1949. In 1947, Suhner and Studer parted ways. Swiss journalist and author Peter Holenstein describes how this happened in his book on the lifework of co-founder Willi Studer: In June 1947, Emil Haefely, founder of the company Emil Haefely & Cie AG, which was one of Metrohm's first customers, asked Willi Studer, whom he had known for many years, to build a prototype for a cathode-ray oscilloscope. This being new technology for Metrohm, Bertold Suhner opposed the idea, fearing that the development wouldn't be possible within reasonable time and budget constraints. Indeed, while the development of the simpler instruments in Metrohm's portfolio had never taken Studer more than a few weeks, Studer still hadn't finished the prototype after several months at the end of November 1947. At this point, his colleague Suhner lost all hope that the project would come to a successful conclusion. A break between the co-founders was the result, and led Studer to leave the company at the end of December 1947.
=== Processing issues and solutions === Nanocapsules tend to aggregate and become unstable. Thus, substances within capsules can leak. To control the instability, nanocapsules can be dried either through spray drying or freeze-drying (lyophilization). Spray drying – Solutions are sprayed into a drying medium. This method is more widely used in the food industry and used for encapsulation of many food products as flavors, minerals, colors, and vitamins. This method makes nanocapsules more stable, and increases shelf-life of foods. Freeze-drying – This process involves dehydration of materials that are heat-sensitive. Unlike spray drying, water is removed through the sublimation process without changing the structure or shape of the nanoparticles. Freeze-drying involves four states: freezing, primary drying, secondary drying, and storage. Because of the multiple stages involved, this method is considered to demand more energy and time.
Sources: en.wikipedia.org
== Critical reception and reviews == Nikhil Krishnan of The Daily Telegraph rated The Half Known Life one out of five stars. Bilal Qureshi of The Washington Post wrote "“The Half Known Life” is a masterful merging of Iyer’s past and current concerns, a book of inner journeys told through extraordinary exteriors, of hopeful optimism for a world rooted in the paradise of being home.". The book has been reviewed by Mark Epstein of The New York Times, Tim Adams of The Guardian, Danny Heitman of The Wall Street Journal, Mini Kapoor of The Hindu, Caroline Eden of Financial Times, Thúy Đinh of National Public Radio and Paul Clement of The Irish Times.
George Galloway (born 16 August 1954) is a British politician, broadcaster, and writer. He has been leader of the Workers Party of Britain since he founded it in 2019, and is a former leader of the Respect Party. Until 2003, he was a member of the Labour Party. From 1987 to 2010, from 2012 to 2015, and briefly in 2024, Galloway served as Member of Parliament (MP) for five different constituencies. As of 2026, he is living in "self-imposed exile" in Russia. Galloway was born in Dundee, Scotland. After becoming the youngest ever chair of the Scottish Labour Party in 1981, he was general secretary of the charity War on Want from 1983 until his election as MP for Glasgow Hillhead at the 1987 general election; he was re-elected three times. The Labour Party expelled him in 2003 due to comments he made in opposition to the invasion of Iraq. Galloway joined the Respect Party in 2004, and was its leader from 2013 to 2016. He was elected as MP for Bethnal Green and Bow at the 2005 general election. After losing in the neighbouring constituency of Poplar and Limehouse at the 2010 general election, he regained a parliamentary seat at the 2012 Bradford West by-election, only to lose it at the 2015 general election. He unsuccessfully stood as an independent candidate at the 2017 and 2019 general elections. Galloway then founded the Workers Party of Britain, and stood unsuccessfully for the party at the 2021 Batley and Spen by-election. Galloway won the 2024 Rochdale by-election. He lost the seat at the 2024 general election.
==== Safety ==== The safety of red yeast rice (RYR) products has not been established. Some supplements have been found to contain high levels of citrinin, which can be toxic to the liver, kidneys, and cellular DNA. Commercial products also have highly variable amounts of monacolins and rarely declare this content on the label, making risk assessment difficult. Ingredient suppliers have been suspected of "spiking" red yeast rice preparations with purified lovastatin. One published analysis reported several commercial products as being almost entirely monacolin K—which would occur if the drug lovastatin was illegally added—rather than the expected composition of many monacolin compounds. There are reports in the literature of muscle myopathy and liver damage resulting from red yeast rice usage. From a review: "The potential safety signals of myopathies and liver injury raise the hypothesis that the safety profile of RYR is similar to that of statins. Continuous monitoring of dietary supplements should be promoted to finally characterize their risk profile, thus supporting regulatory bodies for appropriate actions." The European Food Safety Authority (EFSA) Panel on Food Additives and Nutrient Sources added to Food concluded that when red yeast rice preparations contained monacolins, the Panel was unable to identify an intake that it could consider as safe. The reason given was case study reports of severe adverse reactions to products containing monacolins at amounts as low as 3 mg/day. Red yeast rice is not recommended during pregnancy or breast-feeding.
amplification The replication of a biomolecule, in particular the production of one or more copies of a nucleic acid sequence, known as an amplicon, either naturally (e.g. by spontaneous duplications) or artificially (e.g. by PCR), and especially implying many repeated replication events resulting in thousands, millions, or billions of copies of the target sequence, which is then said to be amplified.
Sources: en.wikipedia.org
== Embryonic development == During embryo development in mice, CCN1 is highly expressed in the cardiovascular, skeletal, and neuronal systems. CCN1 knockout mice are embryonic lethal due to defects in cardiac septal morphogenesis, deficient blood vessel formation in placenta, and compromised vascular integrity. In Xenopus laevis, CCN1 is required for normal gastrulation and modulation of Wnt signaling.
=== Production and regulation === Corticotropin-Releasing Hormone (CRH) is produced as a component of a prohormone, which is then enzymatically digested and undergoes enzymatic changes to make the amidated version. Peripheral CRH and its receptors have been detected in the majority of female reproductive tissues, such as uterus, placenta, and ovary. CRH may be identified in the mother's bloodstream for the whole duration of pregnancy and has an essential role in controlling the timing of childbirth. Placental synthesis of CRH grows during pregnancy. CRH gene is actively transcribed in the hypothalamus and its expression is controlled by negative feedback mechanism mediated by glucocorticoids. Glucocorticoids enhance the expression of CRH via promoting histone acetylation. Outside of pregnancy, CRH is hardly detectable in human circulation.
In herbal medicine, aqueous extracts of bay laurel have been used as an astringent and salve for open wounds. It is also used in massage therapy and aromatherapy. A folk remedy for rashes caused by poison ivy, poison oak, and stinging nettle is a poultice soaked in boiled bay leaves. The Roman naturalist Pliny the Elder listed a variety of conditions which laurel oil was supposed to treat: paralysis, spasms, sciatica, bruises, headaches, catarrhs, ear infections, and rheumatism.
=== Founding === Five Guys was founded in 1986 by Janie and Jerry Murrell. Jerry and the couple's sons Jim, Matt, Chad, and Ben were the original "Five Guys". The Murrells had a fifth son, Tyler, two years later. Today, all five sons, the current "Five Guys", are involved in the business: Matt and Jim travel the United States visiting stores, Chad oversees training, Ben selects the franchisees, and Tyler runs the bakery. The first Five Guys was in Arlington's Westmont Shopping Center. Buns were baked in the same center by Brenner's Bakery. This location closed, in favor of another in Alexandria, Virginia, at the intersection of King and North Beauregard Streets, which closed on September 21, 2013.
Galcanezumab, sold under the brand name Emgality, is a humanized monoclonal antibody used for the prevention of migraine. It is also used for the treatment of cluster headaches. A substance called calcitonin gene-related peptide (CGRP) has been shown to be involved in the development of migraine by widening blood vessels in the brain. Galcanezumab is a monoclonal antibody (a type of protein) designed to attach to and block CGRP, thereby helping blood vessels to return to their normal size. This will stop the symptoms of migraine. Galcanezumab is generally delivered through self-injections. Common side effects include injection site reactions such as pain or redness. Other side effects may include hypersensitivity reactions. Galcanezumab was developed by Eli Lilly. It was approved for medical use in the United States and in the European Union in 2018, becoming the third calcitonin gene-related peptide (CGRP) inhibitor to be approved by the US Food and Drug Administration (FDA).
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.